← All trials
NCT05704829
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 31, 2023
- Primary completion
- Jun 30, 2026
- Completion date
- Jun 30, 2028
- First posted
- Jan 30, 2023
- Last posted
- Sep 21, 2023
- Enrollment
- 402
- Arms / groups
- 4 / —
- Source
- AACT · ctgov ingestion
Sponsors
- West German Study GroupLead sponsor
- AstraZenecaCollaborator
- Ludwig Maximilians UniversityOverall official - principal investigator
- Ludwig Maximilians UniversityOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.